<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973217</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-2015-008</org_study_id>
    <nct_id>NCT02973217</nct_id>
  </id_info>
  <brief_title>Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer</brief_title>
  <official_title>Prospective, Open, Non Comparative Trial to Evaluate Safety and Feasibility of Immunostimulating Interstitial Laser Thermotherapy (imILT) in Stage III Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Laserthermia Systems AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Laserthermia Systems AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue.&#xD;
      Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of&#xD;
      thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a&#xD;
      tumor specific immunologic response. In laboratory animals the imILT method has also been&#xD;
      shown to induce a so called abscopal effect. This means that when one tumor is treated with&#xD;
      imILT other, untreated, tumors also decrease in size.&#xD;
&#xD;
      The purpose of this trial is to evaluate efficiency when it comes to local tumor destruction&#xD;
      of the imILT treatment method in patients diagnosed with pancreatic cancer. The purpose is&#xD;
      also to investigate the functionality and safety as well as understanding of the subsequent&#xD;
      immunological effects.&#xD;
&#xD;
      This trial is prospective, open and non-randomized. Five patients diagnosed with pancreatic&#xD;
      cancer will be treated in this trial, which is estimated to be carried out during a time&#xD;
      period of 36 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response in circulation measured by quantification of inflammatory cell populations</measure>
    <time_frame>36 months</time_frame>
    <description>Quantification of cellular infiltrate and activation markers by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>36 months</time_frame>
    <description>Analysis of the percentage of patients with no new oncological events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of Life (using questionnaires)</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of Quality of Life is evaluated using standardized questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability of the device as evaluated by treatment logs</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluation of the laser system by analysis of treatment logs of the device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Neoplasms Pancreatic</condition>
  <arm_group>
    <arm_group_label>imILT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunostimulating Interstitial Laser Thermotherapy (imILT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunostimulating Interstitial Laser Thermotherapy</intervention_name>
    <arm_group_label>imILT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytohistological diagnosis of ductal pancreatic adenocarcinoma .&#xD;
&#xD;
          -  Stage III disease (see above).&#xD;
&#xD;
          -  The patient is not a candidate for continued chemotherapy or (chemo)radiotherapy due&#xD;
             to lack of demonstrable efficiency or to the side effects of the drugs.&#xD;
&#xD;
          -  Age between 18 and 80 years.&#xD;
&#xD;
          -  Anticipated compliance with treatment and follow-up.&#xD;
&#xD;
          -  Double informed consent for both imILT and possible surgery with radical intent (in&#xD;
             the event of pre-operative overstaging).&#xD;
&#xD;
          -  At least a part of the tumor can be treated with imILT without damage to surrounding&#xD;
             vital structures.&#xD;
&#xD;
          -  Have an ECOG performance status &lt; 1 (l'Eastern Cooperative Oncology Group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not a candidate for laparotomy.&#xD;
&#xD;
          -  Becoming resectable after neoadjuvant chemotherapy.&#xD;
&#xD;
          -  Other simultaneous treatments for the same neoplasm.&#xD;
&#xD;
          -  Simultaneous other malignancies except for basal cell carcinoma.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Active autoimmune disease.&#xD;
&#xD;
          -  Systemic corticosteroid medication.&#xD;
&#xD;
          -  Pregnancy or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut J. Paoli et L. Calmettes (IPC)</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperthermia, Induced</keyword>
  <keyword>Laser Coagulation</keyword>
  <keyword>Laser Therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

